We are live on ! Find out more
AVDL

Avadel Pharmaceuticals
AVDL

Delisted

AVDL was delisted on the 11th of February, 2026.

Back to rankings

87 hedge funds and large institutions have $360M invested in Avadel Pharmaceuticals in 2016 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

14% more capital invested

Capital invested by funds: $316M → $360M (+$44.6M)

4% more funds holding

Funds holding: 84 → 87 (+3)

8% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 25

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

97% less call options, than puts

Call options by funds: $37K | Put options by funds: $1.08M

Holders
87
Holders Change
+3
Holders Change %
+3.57%
% of All Funds
2.32%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
7
Increased
27
Reduced
25
Closed
4
Calls
$37K
Puts
$1.08M
Net Calls
-$1.05M
Net Calls Change
-$65K

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$17.8M
2
IHM
Iguana Healthcare Management
New York
+$4.25M
3
AC
Armistice Capital
New York
+$3.29M
4
GTC
Ghost Tree Capital
New York
+$2.94M
5
Morgan Stanley
Morgan Stanley
New York
+$2.21M

Top Sellers

Rank Fund Capital Flow
1
JGC
J. Goldman & Co
New York
-$6.2M
2
Millennium Management
Millennium Management
New York
-$5.83M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
-$4.96M
4
EA
Emerald Acquisition
Washington
-$3.53M
5
FPC
Falcon Point Capital
California
-$2.42M
Name Holding Trade Value Shares
Change 		Change in
Stake
D.E. Shaw & Co
26
D.E. Shaw & Co
New York
$2.74M +$884K +67,676 +44%
KFA
27
Kelleher Financial Advisors
New York
$2.32M -$6.53K -500 -0.3%
Ameriprise
28
Ameriprise
Minnesota
$2.17M +$146K +11,166 +7%
Millennium Management
29
Millennium Management
New York
$2.03M -$5.83M -446,488 -73%
Janney Montgomery Scott
30
Janney Montgomery Scott
Pennsylvania
$1.68M -$1.37M -104,700 -44%
B
31
Bailard
California
$1.5M +$231K +17,700 +17%
CS
32
Candriam SCA
Luxembourg
$1.38M – – –
DMK
33
David M. Knott
$1.24M – – –
California Public Employees Retirement System
34
California Public Employees Retirement System
California
$1.15M -$83.6K -6,400 -6%
COPPSERS
35
Commonwealth of Pennsylvania Public School Employees Retirement System
Pennsylvania
$966K – – –
TI
36
Turner Investments
Pennsylvania
$869K -$618K -47,280 -40%
GH
37
GAM Holding
Switzerland
$740K -$780K -59,700 -50%
Stifel Financial
38
Stifel Financial
Missouri
$694K +$91.5K +7,000 +14%
CCI
39
Columbus Circle Investors
$615K -$173K -13,242 -21%
DC
40
Deere & Company
Illinois
$544K – – –
Ohio Public Employees Retirement System (OPERS)
41
Ohio Public Employees Retirement System (OPERS)
Ohio
$521K – – –
EVM
42
Eaton Vance Management
Massachusetts
$430K – – –
State of New Jersey Common Pension Fund D
43
State of New Jersey Common Pension Fund D
New Jersey
$408K – – –
CS
44
Credit Suisse
Switzerland
$398K +$50.6K +3,872 +14%
Goldman Sachs
45
Goldman Sachs
New York
$392K +$126K +9,630 +44%
SGAM
46
Smith Group Asset Management
Texas
$377K +$8.49K +650 +2%
State Street
47
State Street
Massachusetts
$366K -$14.9K -1,137 -4%
Bank of America
48
Bank of America
North Carolina
$364K -$4.42K -338 -1%
ProShare Advisors
49
ProShare Advisors
Maryland
$315K -$59K -4,518 -15%
YMRC
50
Yorktown Management & Research Company
Virginia
$310K – – –
1
2
3 4

AVDL Hedge Fund Activity: Q3 2016 in Review

87 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q3 2016, worth a combined $360M — up 14% from $316M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new AVDL positions and 4 closed out — a net gain of 3 holders — while 27 added to existing stakes and 25 trimmed.

The largest buyer was Perceptive Advisors, opening a new position worth an estimated $17.8M. The largest seller was J. Goldman & Co, cutting an estimated $6.2M.

  • 87 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q3 2016, up from 84 in Q2 2016.
  • Funds reported $360M of Avadel Pharmaceuticals stock for Q3 2016, up 14% quarter-over-quarter.
  • 7 funds opened new Avadel Pharmaceuticals positions in Q3 2016 and 4 closed out, a net change of +3 holders.
  • The largest Avadel Pharmaceuticals buyer in Q3 2016 was Perceptive Advisors, an estimated $17.8M added.
  • The largest Avadel Pharmaceuticals seller in Q3 2016 was J. Goldman & Co, an estimated $6.2M sold.

Based on aggregated 13F filings for Q3 2016.